Skip to main content
women seating in front of microscope with all protecting gear

Interventional Cardiology Therapies

Our focus

Minimally invasive technologies to improve the lives of patients living with heart and vascular conditions.

Jim’s story

We’re committed to advancing interventional cardiology therapies through less invasive technologies that improve outcomes, deliver care to more patients, reduce costs, and help millions live healthier lives.

Delivering meaningful innovation

Modern approach to percutaneous coronary intervention (PCI).

A comprehensive portfolio of PCI devices and training designed to help interventional cardiologists provide patients with complex coronary artery disease the best possible treatment and quality of life.

Peace of mind.

The SENTINEL™ Cerebral Protection System (CPS) is the first and only commercially available device in the U.S. offering protected transcatheter aortic valve replacement (TAVR) – proven embolic protection against the risk of TAVR-related stroke.

Healing with confidence.

 Available in a portfolio with distinct options to treat the unique needs of patients, the SYNERGY™ Bioabsorbable Polymer Stent is intentionally designed with thin struts and a fast-absorbing bioabsorbable polymer coating, which enable rapid healing and shortened dual-antiplatelet therapy.  

Designed to optimize TAVR.

The ACURATE neo2™ Aortic Valve System* is a self-expanding, supra-annular valve designed to provide effective sealing, placement accuracy, predictable release, and expanded patient access for patients with aortic stenosis who are indicated for TAVR.

~200

lives impacted every hour by Boston Scientific Interventional Cardiology Therapies.1

> 60k

patients treated worldwide with the ACURATETM Aortic Valve System1 *

> 100k

patients treated worldwide with the SENTINELTM Cerebral Protection System. 1

>18.4 million

coronary drug eluting stent implants globally.1

>5.6 million

SYNERGY™ Bioabsorbable Polymer Stent implants.1


Conditions we treat

  • Cardiovascular Diseases
  • Coronary Artery Disease

~6M

patients undergo PCIs worldwide annually.2

1.8M

patients worldwide affected with calcium.2

4.5M

patients with aortic stenosis.3

3.5M

patients with moderate-severe mitral regurgitation.4


Solutions we offer

  • Transcatheter Aortic Valve Replacement (TAVR)
  • Cerebral Embolic Protection (CEP)
  • Drug-Eluting Technologies
  • Complex Percutaneous Coronary Intervention (PCI)
  • PCI Guidance
  •  Calcium Treatment

Product spotlights

Sources

  1. Internal Boston Scientific data
  2. Internal BSC estimate
  3. https://pubmed.ncbi.nlm.nih.gov/29622096/
  4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5974123/
  5. Van Mieghem N. Snapshots from Real World High Volume Single Center Experiences with Sentinel Cerebral Embolic Protection During TAVR, Erasmus Medical Center, presented at TVT 2018. 
  6. Seeger J. Snapshots from Real World High Volume Single Center Experiences with Sentinel Cerebral Embolic Protection During TAVR, University of Ulm, presented at TVT 2018. 
  7. Chakravarty T. Snapshots from Real World High Volume Single Center Experiences with Sentinel Cerebral Embolic Protection During TAVR, Cedars Sinai Medical Center, presented at TVT 2018.
  8. SWEET Registry: Cook TCT 2015., Fribourg Experience: Arroyo CRT 2016. Belfast Experience: Noad TCT 2015., EVOLVE II: Kereiakes, et al. Circ Cardiovasc Interv. 2015;8:e002372.DOI:10.1161/CIRCINTERVENTIONS.114.002372.,EVOLVE FHU: Meredith et al. J Am Coll Cardiol. 2012;59(15):1362., EVOLVE II QCA: Meredith ACC 2015., SCAAR Registry: James TCT 2016 BIO-RESORT presented by Clemens von Birgelen, MD PhD, TCT 2016.

*Caution: In the EU, ACURATE neo2 is CE-marked. In the US, ACURATE neo2 is an Investigational Device, approved for Investigational Use only. Not available for sale. Federal law (U.S.) restricts these devices to sale by or on the order of a physician.